Education
About Us
Working with TipRanks
Follow Us
Rezolute, Inc. (RZLT)
:RZLT
RZLT Stock Chart & Stats
Day’s Range― - ―
52-Week Range$2.22 - $6.70
Previous CloseN/A
Volume107.87K
Average Volume (3M)802.85K
Market Cap
$562.86M
Enterprise Value$248.10M
Total Cash (Recent Filing)$86.89M
Total Debt (Recent Filing)$1.77M
Price to Earnings (P/E)―
Beta0.76
Next Earnings
Sep 11, 2025EPS Estimate
-0.22Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.27
Shares Outstanding86,995,990
10 Day Avg. Volume555,518
30 Day Avg. Volume802,852
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap0.44
Enterprise Value/Revenue4.28K
Enterprise Value/Gross Profit8.86K
Enterprise Value/Ebitda-3.27
Forecast
1Y Price Target
$14.00Price Target Upside101.15% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
Bulls Say, Bears Say
Bulls Say
Clinical Trial SuccessThe baseline demographic and characteristics of the over-enrolled Ph3 sunRIZE study suggest a largely similar patient group vs. the open-label Ph2b RIZE study, indicating a high likelihood of success.
Efficacy EvidenceThere is confidence in ersodetug's efficacy due to previous data showing significant reduction in hypoglycemia events.
Regulatory AdvancementRZLT has reached an alignment with the FDA on moving directly into a Ph3 registrational study based on positive data from an active expanded access program.
Bears Say
Market Size LimitationsThe initial total addressable market for ersodetug consists of approximately 1,500 diazoxide-unresponsive/intolerant patients at an annualized price point likely in the mid-six-figure range.
Rezolute News
RZLT FAQ
What was Rezolute, Inc.’s price range in the past 12 months?
Rezolute, Inc. lowest stock price was $2.21 and its highest was $6.70 in the past 12 months.
What is Rezolute, Inc.’s market cap?
Rezolute, Inc.’s market cap is $562.86M.
When is Rezolute, Inc.’s upcoming earnings report date?
Rezolute, Inc.’s upcoming earnings report date is Sep 11, 2025 which is in 19 days.
How were Rezolute, Inc.’s earnings last quarter?
Rezolute, Inc. released its earnings results on May 20, 2025. The company reported -$0.27 earnings per share for the quarter, missing the consensus estimate of -$0.229 by -$0.041.
Is Rezolute, Inc. overvalued?
According to Wall Street analysts Rezolute, Inc.’s price is currently Undervalued.
Does Rezolute, Inc. pay dividends?
Rezolute, Inc. does not currently pay dividends.
What is Rezolute, Inc.’s EPS estimate?
Rezolute, Inc.’s EPS estimate is -0.22.
How many shares outstanding does Rezolute, Inc. have?
Rezolute, Inc. has 86,995,990 shares outstanding.
What happened to Rezolute, Inc.’s price movement after its last earnings report?
Rezolute, Inc. reported an EPS of -$0.27 in its last earnings report, missing expectations of -$0.229. Following the earnings report the stock price went up 1.519%.
Which hedge fund is a major shareholder of Rezolute, Inc.?
Currently, no hedge funds are holding shares in RZLT
Rezolute Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$14.00 (101.15% Upside)
$14.00 (101.15% Upside)
Blogger Sentiment
Bullish
RZLT Sentiment 70%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Increased
By 2.9M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $4.0M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Neutral
Last 7 Days ▲ 1.4%
Last 30 Days <0.1%
Last 30 Days <0.1%
News Sentiment
Neutral
Bullish news 50%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Positive
20 days / 200 days
Momentum
60.00%
12-Months-Change
Fundamentals
Return on Equity
-95.15%
Trailing 12-Months
Asset Growth
7.98%
Trailing 12-Months
Company Description
Rezolute, Inc.
Rezolute, Inc., a clinical stage biopharmaceutical company, develops transformative therapies for metabolic diseases associated with chronic glucose imbalance in the United States. The company's lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder. It is also developing RZ402, a selective and potent plasma kallikrein inhibitor, which is in Phase 1 clinical trial for the chronic treatment of diabetic macular edema. The company was formerly known as AntriaBio, Inc. and changed its name to Rezolute, Inc. in December 2017. Rezolute, Inc. was founded in 2010 and is headquartered in Redwood City, California.
RZLT Stock 12 Month Forecast
Average Price Target
$14.00
▲(101.15% Upside)
Technical Analysis
AC Immune SA
―
Diamedica Therapeutics
―
Fulcrum Therapeutics
―
Tango Therapeutics
―
Inhibikase Therapeutics
―
Ownership Overview
11.10% Insiders
36.59% Mutual Funds
3.02% Other Institutional Investors
41.62% Public Companies and Individual Investors